Stephens Reaffirms Overweight Rating for Ardent Health Partners (NYSE:ARDT)

Stephens restated their overweight rating on shares of Ardent Health Partners (NYSE:ARDT - Free Report) in a research report report published on Tuesday morning,Benzinga reports. The firm currently has a $21.00 price objective on the stock.

Other equities analysts have also issued reports about the company. Royal Bank of Canada restated an "outperform" rating and set a $21.00 price target on shares of Ardent Health Partners in a research report on Thursday, May 15th. Mizuho reduced their price target on Ardent Health Partners from $19.00 to $18.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Morgan Stanley dropped their price objective on Ardent Health Partners from $23.50 to $22.00 and set an "overweight" rating for the company in a report on Tuesday, January 21st. Finally, Guggenheim increased their price objective on Ardent Health Partners from $16.00 to $18.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $20.67.

Ardent Health Partners Price Performance

Shares of Ardent Health Partners stock traded down $0.19 during trading on Tuesday, hitting $14.61. 280,957 shares of the stock traded hands, compared to its average volume of 393,743. The company has a quick ratio of 1.78, a current ratio of 1.91 and a debt-to-equity ratio of 0.78. The stock has a market cap of $2.09 billion and a price-to-earnings ratio of 8.96. The firm's fifty day moving average is $13.24 and its 200-day moving average is $14.74. Ardent Health Partners has a 52 week low of $11.31 and a 52 week high of $20.72.

Ardent Health Partners (NYSE:ARDT - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.21 by $0.08. The firm had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.50 billion. Research analysts expect that Ardent Health Partners will post 1.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ARDT. JPMorgan Chase & Co. purchased a new position in shares of Ardent Health Partners in the 3rd quarter valued at approximately $154,000. Oliver Luxxe Assets LLC bought a new position in Ardent Health Partners during the 4th quarter valued at approximately $1,465,000. R Squared Ltd bought a new position in Ardent Health Partners during the 4th quarter valued at approximately $37,000. Allspring Global Investments Holdings LLC increased its position in Ardent Health Partners by 9.2% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 779,601 shares of the company's stock valued at $13,136,000 after buying an additional 65,833 shares in the last quarter. Finally, Rhumbline Advisers increased its position in Ardent Health Partners by 23.9% during the 4th quarter. Rhumbline Advisers now owns 16,913 shares of the company's stock valued at $289,000 after buying an additional 3,266 shares in the last quarter.

Ardent Health Partners Company Profile

Ardent Health Partners, Inc owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee.